Tesamorelin may support certain aspects of longevity, regeneration, and healthy aging by stimulating natural growth hormone (GH) and insulin-like growth factor-1 (IGF-1) pathways. Studies suggest it can improve visceral adipose tissue metabolism, support mitochondrial function, aid in maintaining lean muscle mass, and potentially benefit cognitive health. Although tesamorelin is FDA-approved solely for the treatment of excess visceral adipose tissue in HIV patients, not as an anti-aging therapy, several clinical studies indicate that tesamorelin-induced activation of the GH–IGF-1 axis may positively impact aging-related biological processes, including body composition, liver function, inflammation, cellular energy metabolism, and brain health [1–8]. For this reason, the topic of „Tesamorelin for longevity” is gaining increasing attention in the longevity, healthy aging, and metabolic optimization communities.
Tesamorelin acts as a stabilized analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release endogenous GH in a more physiological, pulsatile rhythm [1,2]. Elevated GH levels then increase circulating IGF-1, which is involved in tissue regeneration, protein synthesis, muscle maintenance, mitochondrial energy production, and metabolic regulation. Unlike direct injections of recombinant growth hormone, tesamorelin activates the body's own hormonal pathways earlier in the hormonal axis, which may allow for more natural endocrine regulation [1–3].
One of the most important areas related to aging, studied in the context of tesamorelin, is the reduction of visceral adipose tissue (VAT). Visceral fat is deep-seated adipose tissue surrounding internal organs, strongly associated with cardiovascular disease, insulin resistance, chronic inflammation, fatty liver disease, and accelerated biological aging. In a pooled analysis of Phase III trials involving HIV-positive individuals with abdominal obesity, Falutz et al. (2010) demonstrated that tesamorelin reduced visceral fat by approximately 15.4% over 26 weeks, while improving triglyceride levels and cholesterol ratios without a significant deterioration in glucose metabolism [3]. Long-term studies have shown that this reduction could persist for up to 52 weeks with continued therapy [4]. Reducing visceral fat is considered an important component of healthy aging, as excess VAT promotes chronic inflammation and cardiometabolic disorders.
Tesamorelin may also support healthy aging by influencing liver function and mitochondrial health. In randomized trials of individuals with HIV-associated nonalcoholic fatty liver disease (NAFLD), Stanley et al. (2019) demonstrated that tesamorelin reduced hepatic fat by approximately 37% over 12 months [5]. Fourman et al. (2020) additionally noted improvements in the expression of genes related to oxidative phosphorylation, mitochondrial metabolism, and energy production, while simultaneously reducing inflammatory pathways and fibrosis [6]. Oxidative phosphorylation is the process by which cells produce energy in the mitochondria. Since mitochondrial dysfunction and chronic inflammation are strongly associated with aging, these results suggest that tesamorelin may influence key metabolic pathways related to longevity, beyond mere fat reduction.
Another area of interest is the potential impact of tesamorelin on muscle quality, recovery, and physical fitness. Aging is often associated with sarcopenia, a decline in muscle density, slower recovery, and reduced physical capacity. Adrian et al. (2019) demonstrated that tesamorelin improved both muscle density and muscle cross-sectional area in adults with HIV and excess abdominal fat [7]. Improved muscle quality and the preservation of lean body mass may support mobility, recovery capacity, and resilience during aging. GH and IGF-1 signaling are also involved in tissue regeneration, collagen synthesis, and cellular repair processes, making GH secretagogues frequently investigated for their potential to support recovery and performance.
Tesamorelin has also shown potential effects on cognitive and neurological functions related to healthy aging. In a randomized, placebo-controlled study including older adults with and without mild cognitive impairment, Baker et al. (2012) reported improvements in executive functions and selected aspects of memory, along with an increase in IGF-1 levels within the physiological range [8]. Further research by Friedman et al. (2013) suggested a beneficial effect of tesamorelin on brain neurochemistry, including an increase in gamma-aminobutyric acid (GABA) levels and a reduction in markers associated with neuroinflammation [9]. These findings suggest that modulation of the GH–IGF-1 axis may influence cognitive aging, neuronal signaling, and brain metabolism.
Tesamorelin may also support overall metabolic resilience and hormonal optimization. Makimura et al. (2014) demonstrated that tesamorelin-induced IGF-1 increase was associated with improvements in mitochondrial phosphocreatine recovery and cellular energy metabolism in obese adults with diminished GH secretion [10]. Other studies have also shown improvements in adiponectin levels, inflammatory markers, lipid profiles, and cardiovascular risk markers along with visceral fat reduction [3,5,11]. Adiponectin is a hormone associated with improved insulin sensitivity and metabolic health. Collectively, these metabolic changes may support healthier aging by improving energy utilization, limiting inflammation, and increasing metabolic flexibility.
Despite promising results, tesamorelin is not officially approved as an anti-aging therapy or longevity-supportive treatment, and most studies have been conducted in individuals with HIV-associated lipodystrophy or metabolic diseases, rather than in healthy aging populations. Furthermore, as tesamorelin increases GH and IGF-1 activity, appropriate monitoring remains important during therapy. Excessive GH or IGF-1 activity can theoretically increase the risk of edema, joint pain, insulin resistance, or abnormal tissue growth in susceptible individuals [1,2]. Clinical trials generally indicate that tesamorelin is relatively well-tolerated, however, routine monitoring of glucose and IGF-1 levels remains a standard recommendation.
In summary, current data suggest that tesamorelin may support healthy aging by improving visceral fat metabolism, protecting lean muscle mass, supporting mitochondrial and liver function, enhancing recovery, and potentially supporting cognitive health through physiological activation of the GH–IGF-1 axis. Despite promising results, tesamorelin remains primarily a metabolic therapy used for specific medical indications, rather than a validated longevity treatment. Further long-term studies are still needed in healthy aging populations.
Disclaimer
The content is for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. Tesamorelin is an FDA-approved prescription medication for specific medical indications and has not been officially approved as an anti-aging or longevity therapy. Hormone therapies affecting growth hormone and IGF-1 pathways may carry risks and should only be used under the supervision of a qualified healthcare professional with appropriate laboratory monitoring and individual medical assessment.
References
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. (2018). Tesamorelin. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548730/
- PubChem. (2025). Tesamorelin Compound Summary. National Center for Biotechnology Information, National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
- Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
- Falutz, J., Allas, S., Mamputu, J. C., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
- Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Agyapong, G., Torriani, M., Chung, R. T., & Grinspoon, S. K. (2019). Effect of tesamorelin on nonalcoholic fatty liver disease in HIV-positive individuals: A randomized, double-blind, multicenter study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
- Fourman, L. T., Billingsley, J. M., Agyapong, G., Ho Sui, S. J., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Corey, K. E., Torriani, M., Kleiner, D. E., Hadigan, C. M., Stanley, T. L., Chung, R. T., & Grinspoon, S. K. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5(16), e140134. https://doi.org/10.1172/jci.insight.140134
- Adrian, S., Scherzinger, A., Sanyal, A., et al. (2019). Growth hormone-releasing hormone analogue tesamorelin reduces fat and increases muscle area in adults with HIV. The Journal of Frailty & Aging, 8(3), 154–159. https://doi.org/10.14283/jfa.2018.45
- Baker, L. D., Barsness, S. M., Borson, S., et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: Results of a controlled study. Archives of Neurology, 69(11), 1420–1429. https://doi.org/10.1001/archneurol.2012.1970
- Friedman, S. D., Baker, L. D., Borson, S., et al. (2013). Effects of growth hormone-releasing hormone on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurology, 70(7), 883–890. https://doi.org/10.1001/jamaneurol.2013.1425
- Makimura, H., Murphy, C. A., Feldpausch, M. N., & Grinspoon, S. K. (2014). Effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. The Journal of Clinical Endocrinology & Metabolism, 99(1), 338–343. https://doi.org/10.1210/jc.2013-3436
- Stanley, T. L., Falutz, J., Mamputu, J. C., Soulban, G., Potvin, D., & Grinspoon, S. K. (2011). Effect of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: Relationship with visceral adipose tissue reduction. AIDS, 25(10), 1281–1288. https://doi.org/10.1097/QAD.0b013e328347f3f1